Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - will release its financial results for the first quarter of 2025, on May 21, 2025, conference call at 9:00 AM Eastern Time

Company: Evogene Ltd. Date: 2025-05-08 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

## **Evogene Schedules First Quarter 2025 Financial Results Release**

*Zoom conference call scheduled for May 21, 2025, 9:00 AM ET*

**Rehovot, May 8, 2025 - Evogene Ltd**. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on **Wednesday, May 21, 2025**.

Later that day, Company management will host a **conference call to discuss the results at 9:00 AM Eastern Time** (4:00 PM Israel time).

To join the conference, please register in advance:

<https://www.veidan-conferenceing.com/evogene>

The entire conference will be available online on the company's website a few days after.

## **About Evogene:**

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - *MicroBoost AI*, *ChemPass AI* and *GeneRator AI*. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (*MicroBoost AI*), small molecules (*ChemPass AI*), and genetic elements (*GeneRator AI*).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

1. **Biomica Ltd.** ([www.biomicamed.com\)](http://www.biomicamed.com/) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by *MicroBoost AI*;

![](_page_1_Picture_0.jpeg)

- 2. **Lavie Bio Ltd.** [\(www.lavie-bio.com](http://www.lavie-bio.com/))developing and commercially advancing, microbiomebased ag-biologicals powered by *MicroBoost AI*;
- 3. **AgPlenus Ltd.** ([www.agplenus.com](http://www.agplenus.com/)) developing next-generation ag chemicals for effective and sustainable crop protection powered by *ChemPass AI*;
- 4. **Casterra Ag Ltd.** [\(www.casterra.co\)](http://www.casterra.co/) developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by *GeneRator AI*.

For more information, please visit: [www.evogene.com](http://www.evogene.com/).

## **Contact**

[ir@evogene.com](mailto:ir@evogene.com)

Tel: +972-8-9311901

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now